Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.36 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293061 | 0.83 | TOP2A (0.37) | TOP2A | |
| SCHEMBL3291408 | 0.81 | TOP2A (0.37) | TOP2A | |
| SCHEMBL3289662 | 0.79 | TOP2A (0.35) | TOP2AADRA1DADRA1AADRA1B | |
| SCHEMBL3292373 | 0.73 | BCL2L1 (0.34) | ADRA1DADRA1AADRA1B | |
| SCHEMBL3291027 | 0.73 | TAAR1 (0.33) | ADRA1DADRA1AADRA1B | |
| SCHEMBL23533600 | 0.73 | GLS (0.39) | TOP2A | |
| SCHEMBL29804053 | 0.73 | GLS (0.39) | TOP2A | |
| SCHEMBL3294452 | 0.71 | ALDH1A1 (0.39) | — | |
| SCHEMBL31316806 | 0.70 | HRH3 (0.36) | TOP2A | |
| SCHEMBL20786537 | 0.68 | CA2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728155-B2 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH LLC (US) | 2010-06-01 | — | — | US | disclosed |
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH (US) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | HTR2C, HTR1A, HTR1B | TOP2A 2686/4885DUT 1720/4885ADRA1D 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.